ConsumerMed.org is led by a group venture capitalists, entrepreneurs and key executives. We are committed to building a community focused on building businesses that help individuals take control of their health.
Why ConsumerMed? Because, to a large degree, healthcare is a miserable arena for everyone involved.
How would things be different if the individual health consumer were driving the decisions and priorities?
Jim has been with Technology Partners since 2002. Jim leads the firm's efforts in Consumer Medicine, investing in both medical device and biopharmaceutical companies.
He serves on the boards of ElCelyx, Essentialis, Incline Therapeutics (acquired by The Medicines Company), Revance Therapeutics, Transcend Medical, and TRIA Beauty while also having led Technology Partner's investment in two companies that have since gone public; Iomai (IOMI) and Cadence Pharmaceuticals (CADX). Jim is also an advisor to the Lester Center at University of California, Berkeley and the National Science Foundation (NSF) in Washington, DC.
Previously, Jim was Managing Director at CIT Venture Capital, leading the Group's effort in Life Science investing. Also, Jim was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Jim earned a B.S. from Duke University and a M.A. and a Ph.D. from Harvard University in Biology. He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley. Jim has published several research papers and had his research highlighted in major media outlets, including: Nature, The New York Times, Scientific American, and CNN.
healthcare is changing fast and individuals are facing ever more complicated questions around cost, products, services and their own health behaviors... I wanted to amplify the conversation about how to help consumers to be their healthiest selves and to explore beyond the boundaries of the traditional healthcare system to find new, disruptive ideas
Nina Kjellson has been part of InterWest's life sciences team since 2002, focusing primarily on investments in biopharmaceuticals. She is a board member of Alvine Pharmaceuticals, Cebix, Eiger Biopharmaceuticals, Labrys, Lycera, PrimeraDx and Trius Therapeutics (TSRX). Nina led InterWest's investment in APT Pharmaceuticals where she is an observer on the board and co-sponsored InterWest's investments in TESARO and Sera Prognostics where she is also a board observer. Previous investments include Aspreva (ASPV; sold to Galenica), NovaCardia (sold to Merck) and CNS Therapeutics (sold to Covidien). Nina also leads InterWest's initiative in health care IT, is a director of the Consumer Medicine Summit, a forum to address the convergence of health care and consumer innovation and serves as a mentor to the Nike+ Accelerator and to Blueprint Health.
Prior to joining InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University.
Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. Albert draws on his scientific, medical, and operating experience when working with his portfolio companies.
He was an investor in Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals and Prestwick Pharmaceuticals. Other investments include MEI Pharma (MEIP), YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). He currently serves on the board of several private biopharmaceutical and medical device companies. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience. During his studies, he was elected to Alpha Omega Alpha and won the prestigious Outstanding Graduate Student Award. His research in molecular biophysics has been published in highly respected journals such as Nature and Neuron.
Previously a Managing Director, Camille Samuels is now an Affiliated Director with Versant Ventures and represents Versant on the Achaogen, Kythera Pharmaceuticals and Semprae Laboratories Boards. She previously served as a board member or board observer at several Versant portfolio companies including Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acquired by Affymetrix), and Transcept (TSPT). Prior to Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) and held marketing and corporate development roles at Genzyme and Millennium Predictive Medicine. She also spent three years as a management consultant to healthcare and consumer companies at LEK Consulting. Cami earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.
Paulo Simas joined WCG as it's Chief Creative Officer in 2009, after the acquisition of his agency ODA. Since then he has been the creative force behind the agency's explosive growth. A designer by trade, Paulo is equally comfortable riffing about concepts with his team, as he is sitting down with the C-Suite to map out sales and business strategies fueled by an integrated communication platform. His high-octane personality inspires colleagues and clients, driving global projects to break free from the norm. With a deep understanding of branding, analytics and business strategy, his wizardry lies in the development of targeted communication that is impactful, relevant and drives meaningful engagement.
Paulo's deep knowledge in healthcare allows him to understand what drives a clinical decision, while his experience in the consumer and tech space give him unique insights into behavioral change. The dozens of international and industry awards he has received over the years are a testament to his work for such luminary clients such as Acclarent, Advanced Biohealing, Conceptus, Disney, ev3 (formerly Fox Hollow), HP, Hitachi, Medtronic, Oynx, Pfizer, Qualcomm, Volcano and Warner Brothers.
Dr. Yun is a president at Palo Alto Investors where he has led healthcare investing since 1998. He received his AB at Harvard and MD at Duke Medical School. During 1995 through 2005 he completed his residency and fellowship in radiology and served on the Clinical Faculty at Stanford. Current board positions include FlowMedica, Synapse Biomedical, SV2, and Individual Philanthropy Institute.